Search

Displaying results 1881 - 1890 of 7604 in total
  1. Drug

    Obecabtagene autoleucel

    go.drugbank.com/drugs/DB17362
    ApprovedInvestigational

    [A265040,A265045] It works by targeting B-cell-specific CD19 surface markers present on malignant B cells. … [A265050] On November 8, 2024, obecabtagene autoleucel was approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

    Synonyms: AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) OBTAINED BY APHERESIS TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING, A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING O
  2. Drug

    Ferric cation

    go.drugbank.com/drugs/DB13949
    ApprovedWithdrawn

    By mass, it is the most common element on Earth. … Non-haem iron in food is mainly in the ferric state, which is the insoluble form of iron, and must be reduced to the ferrous cation for absorption [T28].

  3. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245144] Hemolysis in patients with CAD is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and extravascular hemolysis. … [L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116]

  4. Drug

    Encainide

    go.drugbank.com/drugs/DB01228
    ApprovedWithdrawn

    The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.

    Synonyms: (±)-4-methoxy-N-(2-(2-(1-methyl-2-piperidinyl)ethyl)phenyl)benzamide, 4-Methoxy-N-{2-[2-(1-methyl-piperidin-2-yl)-ethyl]-phenyl}-benzamide
  5. Drug

    Tick-borne encephalitis vaccine (whole virus, inactivated)

    go.drugbank.com/drugs/DB16611
    ApprovedInvestigational

    [A237520] Originally developed by Baxter International Inc., TICOVAC was subsequently acquired by Pfizer Inc. in 2014.[L36120] TICOVAC was granted FDA approval on August 13, 2021.[L36050] … Tick-borne encephalitis (TBE) is a disease caused by the TBE virus (TBEV), transmitted by ticks from the genus _Ixodes_. The disease course is variable.

  6. Drug

    Alfuzosin

    go.drugbank.com/drugs/DB00346
    Approved

    [L31593] It was initially approved by the FDA in 2003 and is marketed by several pharmaceutical companies.[L9251] … [A228483] Alfuzosin is an alpha-1 adrenergic blocker used in the symptomatic treatment of BPH that works by relaxing the muscles in the prostate and bladder neck.

    Synonyms: (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide, N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamideProducts: ALFUZOSIN RATIO UNO 10MG
  7. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523] … [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable

  8. Drug

    Remifentanil

    go.drugbank.com/drugs/DB00899
    ApprovedInvestigational

    Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid given to patients during surgery for pain relief and adjunctive to an anaesthetic.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: REMIFENTANILO 2MG POLVO PARA RECONSTITUIR A SOLUCION INYECTABLE O INFUSION INTRAVENOSA, REMIFENTANILO 5MG POLVO POLVO LIOFILIZADO PARA SOLUCIÓN INYECTABLE O INFUSIÓN INTRAVENOSA.
  9. Target

    Inactive phospholipase C-like protein 1

    go.drugbank.com/bio_entities/BE0001081
    TargetHumans

    Shows no PLC activity to phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol. Component in the phospho-dependent endocytosis process of GABA A receptor (By similarity).

    Synonyms: Phospholipase C-related but catalytically inactive protein
  10. Drug

    Benralizumab

    go.drugbank.com/drugs/DB12023
    ApprovedInvestigational

    [A31293] Benralizumab was FDA approved on November 14, 2017, and was developed by MedImmune, AstraZeneca's global biologic research and development arm.[L1019] … Benralizumab is a humanized recombinant monoclonal antibody of the isotype IgG1k immunoglobulin that specifically binds to the alpha chain of the interleukin 5 receptor (IL-5R) expressed on eosinophils